The NFKBIZ antibody is a crucial tool for studying NFKBIZ (Nuclear Factor Kappa B Inhibitor Zeta), a protein encoded by the NFKBIZ gene. NFKBIZ, also known as IκB-ζ, belongs to the IκB family and regulates the NF-κB signaling pathway, which plays a central role in inflammation, immune responses, and cell survival. Unlike other IκB proteins, NFKBIZ is not constitutively expressed but is induced by stimuli like Toll-like receptor (TLR) ligands, interleukin-17 (IL-17), or tumor necrosis factor (TNF). It acts as both a transcriptional activator and repressor, modulating NF-κB-dependent gene expression. NFKBIZ is particularly important in immune cells, such as macrophages and B cells, and has been implicated in inflammatory diseases (e.g., psoriasis, rheumatoid arthritis) and cancers (e.g., B-cell lymphomas). Antibodies targeting NFKBIZ are used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect its expression, localization, and interactions. These antibodies help researchers investigate NFKBIZ’s role in disease mechanisms, drug response, and its potential as a therapeutic target. Specificity and validation are critical, as NFKBIZ shares structural motifs with other IκB proteins and exists in multiple isoforms. Studies using NFKBIZ antibodies have revealed its involvement in cytokine production, cell differentiation, and pathogen response, highlighting its dual regulatory functions in health and disease.